Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Sumitomo Pharma Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05435729CT.gov A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Drug-Induced Dyskinesia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dsp-9632P (this asset) | Sumitomo Pharma Co., Ltd. | P1 | CC · 47 |
| Levodopa | Sumitomo Pharma Co., Ltd. | P4 | A |
| Carbidopa | AbbVie (prior sponsor, Abbott) | P4 | BBB |
| Emd 128130 | EMD Serono | P3 | BBB |
| 1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- | Novartis Pharmaceuticals | P2 | BBB |
| Amantadine | Adamas Pharmaceuticals, Inc. | P3 | BBB |
| EPA | University of Stellenbosch | P4 | BB |
| Ropinirole | GlaxoSmithKline | P3 | BB |
| Talampanel | Teva Branded Pharmaceutical Products R&D, Inc. | P2 | BB |
+17 more in the Drug-Induced Dyskinesia cohort
Other indications for Dsp-9632P
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dsp-9632P in Drug-Induced Dyskinesia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dsp-9632p-drug-induced-dyskinesia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →